The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | 51,200 | 56,000 |
| Noncash loss on assets held for sale | - | -12,200 |
| Share-based compensation expense | 4,800 | 6,100 |
| Depreciation and amortization | 23,400 | 48,900 |
| Change in fair value of contingent obligations, net | 0 | 0 |
| Amortization of deferred financing costs | 2,500 | 4,700 |
| Deferred income taxes | -10,200 | 4,700 |
| Loss (gain) on sale of business and assets held for sale | -12,200 | - |
| Change in fair value of warrant liability | 4,800 | -6,600 |
| Impairment of long-lived assets | 0 | 0 |
| Loss on disposal of assets | -2,200 | -1,300 |
| Other | -400 | 9,100 |
| Accounts receivable | 71,600 | -45,200 |
| Inventories | 17,600 | 26,900 |
| Prepaid expenses and other assets | 2,100 | -29,200 |
| Accounts payable | -4,000 | -15,800 |
| Accrued expenses and other liabilities | 1,300 | -28,300 |
| Long-term incentive plan accrual | 700 | 1,600 |
| Accrued compensation | 4,500 | -26,300 |
| Income taxes receivable and payable, net | 6,200 | -1,600 |
| Contract liabilities | 1,200 | -100 |
| Net cash provided by operating activities | -2,300 | 95,200 |
| Purchases of property, plant and equipment | 3,400 | 6,500 |
| Proceeds from sale of property, plant and equipment | 0 | 38,200 |
| Milestone payments from prior asset divestiture | 0 | -50,000 |
| Proceeds from sale of business | 0 | - |
| Purchase of convertible note receivable | 0 | 5,000 |
| Net cash provided by investing activities | -3,400 | 76,700 |
| Proceeds from the issuance of debt, net of lender fees | 0 | - |
| Proceeds allocated to warrants issued in conjunction with debt | 0 | - |
| Proceeds allocated to common stock issued in conjunction with debt | 0 | - |
| Principal payments on term loan facility | 0 | 0 |
| Proceeds from revolving credit facility | 0 | 0 |
| Principal payments on revolving credit facility | 0 | 0 |
| Debt issuance costs | 0 | 0 |
| Proceeds from issuance of common stock upon exercise of stock options | 1,000 | - |
| Repurchase of debt | 6,900 | - |
| Purchases of treasury stock | 8,900 | 6,900 |
| Proceeds from share-based compensation activity | -800 | 800 |
| Taxes paid for share-based compensation activity | 300 | 700 |
| Net cash used in financing activities | -15,900 | -6,800 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | -200 | 300 |
| Net change in cash, cash equivalents and restricted cash | -21,800 | 165,400 |
| Cash and cash equivalents at beginning of period | 105,600 | - |
| Cash and cash equivalents at end of period | 249,200 | - |
Emergent BioSolutions Inc. (EBS)
Emergent BioSolutions Inc. (EBS)